Last reviewed · How we verify

NCT04633538: 6-APP

Evaluation of a New 6 Minute Walk Test Smartphone App in Patients With Pulmonary Hypertension

Completed Results posted Last updated 7 March 2025
What this trial tests

trial testing 6MWT smartphone app in Pulmonary Hypertension in 30 participants. Completed in 1 April 2020.

Timeline
15 January 2018
Primary endpoint
28 August 2019
1 April 2020

Quick facts

Lead sponsorOxford University Hospitals NHS Trust
StatusCompleted
Study typeOBSERVATIONAL
Enrollment30
Start date15 January 2018
Primary completion28 August 2019
Estimated completion1 April 2020
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Oxford University Hospitals NHS Trust

Who can join

18 and older, any sex, with Pulmonary Hypertension. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percentage of Participants Who Perform App-based Home 6MWT Primary · 6 months

Percentage of participants who perform app-based home 6MWT.

GroupValue95% CI
6MWT App Group30
Difference in Walked Distance Between 6MWT Test at the Clinic as Measured by Physiologists and the App in Indoor Mode Secondary · At start, at month 3 and at month 6.

Comparison of the indoor app-based 6MWD against simultaneous clinic 6MWD: mean and standard deviation of the difference in distance as measured by physiologists and the app. Differences at 3 time points (start, month 3 and month 6) are lumped together in the calculation of the statistics (mean and standard deviation).

GroupValue95% CI
6MWT App Group14.6± 75.48
Difference in Walked Distance Between 6MWT Test as Measured by Physiologists at the Clinic and App in Outdoor Mode at the Community Secondary · Clinic tests at start, at month 3, at month 6. Community tests undertaken within 7 days of clinic test.

Comparison of pairs of 6MWT distance estimates where one is the result of an observation done by a physiologist in a clinic (start, month 3 and month 6) and the other is measured by the app during an outdoor test performed within 7 days of the physiologist's observation. Measurements at 3 time points (start, month 3 and month 6) are lumped together in the calculation of the statistics (mean and standard deviation).

GroupValue95% CI
6MWT App Group2.45± 47.0
Test-Retest Reliability of Community-Based 6MWT Secondary · 6MWT in the community, at the patient's discretion (recommended once/month), over 6 months

Intraclass correlation of app-base tests in outdoor mode in the community, measured over pairs of outdoor tests performed by the same patient no more than 7 days apart.

GroupValue95% CI
6MWT App Group0.91
Compliance to Monitoring Regime in the Community Secondary · At month 6

Percentage of patients who performed at least 1 app-based 6MWT in the community per month

GroupValue95% CI
6MWT App Group12

Sponsor's own description

Comparison of standard 6 minute walk test with 6 minute walk test smartphone app.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. App-Based Versus Standard Six-Minute Walk Test in Pulmonary Hypertension: Mixed Methods Study.
    Salvi D, Poffley E, Tarassenko L, Orchard E. · · 2021 · cited 28× · PMID 34096876 · DOI 10.2196/22748
  2. Appraisal of digital home-based 6-Minute Walk Test for use in remote healthcare delivery.
    Varnfield M, Mahoney A. · · 2021 · cited 3× · PMID 36711181 · DOI 10.1093/ehjdh/ztab021

Verify or expand the search:

Other recruiting trials for Pulmonary Hypertension

Currently open trials in the same condition.

Other Oxford University Hospitals NHS Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04633538.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing